Scientific Publication

Maryland's SANS Academy pivots to AI and industrial security, tackling a critical skills gap that now links directly to 27% of all cyber breaches.

New research from Baycrest unmasks paratonia, an involuntary condition often mistaken as defiance, signaling a seismic shift in dementia care and treatment.

A landmark drug approval in China offers new hope for IgAN patients. But the real story is how science, strategy, and policy are converging to build a better future.

A new AI can detect Parkinson's progression where the current gold standard fails. In a stunning validation, the study was led by the very scientists who created the old method.

A biometric breakthrough promises to solve crimes faster than ever. But as AI closes cold cases, it opens a Pandora's box of ethical and privacy questions.

Rakovina Therapeutics reports a dramatic financial recovery, slashing costs while boosting AI-driven R&D, positioning its promising cancer pipeline for growth.

Researchers have discovered a metabolic 'Achilles' heel' in a rare liver cancer, offering a new treatment path beyond ineffective chemotherapy.

Endeavor Health's new genetic test provides a "floodlight" on heart disease risk, but with no insurance coverage, who will get to see the light?

A single blood test can now simultaneously track immune response, tumor changes, and resistance, offering new hope for personalizing sarcoma immunotherapy.

A new study on runners reveals how vagus nerve stimulation improves recovery and sleep, pioneering a 'Stress Fitness' approach for athletes.

New preclinical data shows Sharp Therapeutics' oral drug candidate could reverse key pathologies of the fatal genetic disorder, offering hope beyond symptom management.

A landmark study offers reassurance on kids' heart health post-COVID but details a range of persistent symptoms, separating viral effects from pandemic stress.

Celebrating two decades of innovation, RadioMedix unveils promising new alpha therapy data for pancreatic cancer at the SNMMI 2026 annual meeting.

Researchers have validated the first tool to measure period product insecurity, a data-driven breakthrough that promises to transform policy and advocacy.

Vanda Pharmaceuticals' rare disease drug gets a key designation in Japan, unlocking major incentives and promising a new treatment for a severe skin disease.

MBX Biosciences prepares for the Jefferies conference, with investors eyeing updates on its late-stage hypoparathyroidism drug and promising obesity portfolio.

Myers' EnerShed 2.0 is the first BESS to conquer the stringent UL 9540A 6th Edition fire test, a milestone poised to accelerate clean energy adoption.

A new study reveals a sharp drop in prescription fills at just $35, highlighting a critical affordability crisis that even insured patients can't escape.

A $290M war chest fuels a new public biotech aiming to help millions of migraine patients who don't respond to current blockbuster therapies.

NImmune Biopharma's oral drug NIM-1324 shows promising safety and efficacy, targeting a novel pathway to treat IBD and a host of other diseases.